Biomerica (BMRA) Cut to Sell at ValuEngine
Biomerica (NASDAQ:BMRA) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
Shares of Biomerica (NASDAQ:BMRA) traded down $0.13 during trading hours on Friday, hitting $3.31. 3,558 shares of the stock traded hands, compared to its average volume of 15,529. Biomerica has a 52 week low of $1.92 and a 52 week high of $3.85.
Biomerica (NASDAQ:BMRA) last issued its earnings results on Monday, October 16th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. Biomerica had a negative net margin of 18.19% and a negative return on equity of 22.82%. The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.52 million. sell-side analysts expect that Biomerica will post -0.12 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/03/biomerica-bmra-cut-to-sell-at-valuengine.html.
Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biomerica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.